Modern Slavery Statement 2020

We are committed to improving our practices to combat slavery and human trafficking, modern slavery and any other form of human rights abuse, discrimination or exploitation. Rosemont is committed to Human Rights, both in our own operations, as well with our business partners and suppliers. Our commitment will explicitly prohibit the use of child, forced or trafficked labour of any kind, among many other health, safety and ethical labour requirements.

Our structure

We are a leading manufacturer of liquid medicine. We are an independent company although our ultimate parent company is Inflexion Private Equity Partners LLP (Inflexion). Inflexion has its head office in the U.K and they have over 24,000 employees across full portfolio and operate in 160 countries across its portfolio.

Our business

Our Rosemont business is organised into two business units: Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE where our manufacturing and distribution services operate. We also acquire premises at Floor 2, Olympia House, Geldard Lane, Leeds where our Development team are positioned.

Our supply chains

Rosemont maintains a robust supply chain with operational facilities in one country (UK). In addition, we source products, raw materials, and other goods/services from partners and suppliers around the globe.

Our policies on slavery and human trafficking

We are committed to ensuring that there is no modern slavery or human trafficking in our supply chains or in any part of our business. We commit to acting ethically and with integrity in all our business relationships and plan to implement and enforce effective systems and controls to ensure slavery and human trafficking is not taking place anywhere in our supply chains.

Due diligence processes for slavery and human trafficking

We expect our employees, contractors, suppliers and other business partners to respect the human rights of all individuals through our supply chain. Rosemont is committed to doing business with ethical companies. This means ensuring that all products manufactured or services conducted on behalf of Rosemont are done so in a manner that does not violate any law, use any form of child, forced or trafficked labour, risk the health or wellbeing of the person involved, or violate directly or indirectly, any human rights.
To support this commitment, we will propose the following systems to be put in place:

- Identify and assess potential risk areas to our business and supply chain;
- Reduce the risk of slavery and trafficking occurring in our business and supply chain;
- Monitor identified risks to our business and supply chain; and
- Provide adequate protection for whistle blowers

This policy applies to all persons working for, or on behalf of Rosemont Pharmaceuticals, in any capacity. This includes but does not limit the policy applicability to; employees, agency workers, temporary staff, agents, contractors, external consultants, third-party representatives and business partners.

**Training**

To ensure a high level of understanding of the risks of modern slavery and human trafficking in our supply chains and our business, we commit to establishing and providing training to our staff.

This policy does not form part of any employee’s contract of employment and we reserve the right to amend at any time.

**Our effectiveness in combating slavery and human trafficking**

Any issues reported through the Whistleblower Policy is reviewed by a cross-functional team, escalated and thoroughly investigated per our defined procedure.

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes slavery and human trafficking statement for the financial year ending 2020. It was approved by the board on 26 October 2020

_HOWARD TAYLOR_  
CHIEF EXECUTIVE OFFICER  
Rosemont Pharmaceuticals Limited  
26 October 2020